Emergent Biosolutions
EBS
272 hedge funds and large institutions have $2.28B invested in Emergent Biosolutions in 2019 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 104 increasing their positions, 92 reducing their positions, and 58 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 92
3.14% more ownership
Funds ownership: 85.18% → 88.32% (+3.1%)
8% less funds holding
Funds holding: 297 → 272 (-25)
11% less call options, than puts
Call options by funds: $1.71M | Put options by funds: $1.92M
11% less capital invested
Capital invested by funds: $2.57B → $2.28B (-$287M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
40% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$36.4M |
| 2 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$31.1M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$26.4M |
| 4 |
Renaissance Technologies
New York
|
+$22.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$14.9M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$14.6M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$12.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.84M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$8.71M |
EBS Hedge Fund Activity: Q1 2019 in Review
272 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2019, worth a combined $2.28B — down 11% from $2.57B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of EBS and 35 opened new positions — a net loss of 23 holders — while 92 trimmed existing stakes and 104 added.
The largest buyer was Neuberger Berman Group, adding an estimated $36.4M. The largest seller was Goldman Sachs, cutting an estimated $14.9M.
- 272 institutional investors held Emergent Biosolutions (EBS) as of Q1 2019, down from 297 in Q4 2018.
- Funds reported $2.28B of Emergent Biosolutions stock for Q1 2019, down 11% quarter-over-quarter.
- 35 funds opened new Emergent Biosolutions positions in Q1 2019 and 58 closed out, a net change of -23 holders.
- The largest Emergent Biosolutions buyer in Q1 2019 was Neuberger Berman Group, an estimated $36.4M added.
- The largest Emergent Biosolutions seller in Q1 2019 was Goldman Sachs, an estimated $14.9M sold.
Based on aggregated 13F filings for Q1 2019.